in a mesothelioma xenograft model with tumor cell FAP expression (36) and was further determined to be safely tolerated in a phase I clinical trial of autologous FAP(hF1) CAR T-cells against malignant pleural mesothelioma (MPM) (39). Here, FAP is linked to malignant pleural mesothelioma.